GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...

They're leading to reduced grocery spending, healthier food choices, wardrobe changes, and altered dining habits. The drugs ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Medicare Part D will cover popular weight loss drugs like Wegovy and Ozempic starting in 2026, with copays capped at $50 per ...

Starting Jan. 1, New Hampshire’s Medicaid program will stop covering GLP-1 drugs — Wegovy, Zepbound, and others — for weight ...

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...

The Alliance for Women’s Health and Prevention wrote a letter to Gov. Ayotte urging her to reconsider the decision. The organization noted that approximately 30% of women in New Hampshire experience ...

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...